We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 Bivalent Boosts: Preliminary Results From the COVAIL Randomized Clinical Trial.
- Authors
Branche, Angela R; Rouphael, Nadine G; Losada, Cecilia; Baden, Lindsey R; Anderson, Evan J; Luetkemeyer, Anne F; Diemert, David J; Winokur, Patricia L; Presti, Rachel M; Kottkamp, Angelica C; Falsey, Ann R; Frey, Sharon E; Rupp, Richard; Bäcker, Martín; Novak, Richard M; Walter, Emmanuel B; Jackson, Lisa A; Little, Susan J; Immergluck, Lilly C; Mahgoub, Siham M
- Abstract
In a randomized clinical trial, we compare early neutralizing antibody responses after boosting with bivalent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA (mRNA) vaccines based on either BA.1 or BA.4/BA.5 Omicron spike protein combined with wild-type spike. Responses against SARS-CoV-2 variants exhibited the greatest reduction in titers against currently circulating Omicron subvariants for both bivalent vaccines.
- Subjects
UNITED States; IMMUNOGLOBULIN analysis; CONFIDENCE intervals; COVID-19 vaccines; CORONAVIRUS spike protein; CHRONIC diseases; CHEMILUMINESCENCE assay; VACCINE immunogenicity; VACCINE effectiveness; ANTIBODY formation; RANDOMIZED controlled trials; MESSENGER RNA; DESCRIPTIVE statistics; RESEARCH funding; STATISTICAL sampling; POLYMERASE chain reaction
- Publication
Clinical Infectious Diseases, 2023, Vol 77, Issue 4, p560
- ISSN
1058-4838
- Publication type
Article
- DOI
10.1093/cid/ciad209